Semisynthetic modifications of antitubercular lanostane triterpenoids from Ganoderma

Area of Science:

• Natural Product Chemistry
• Medicinal Chemistry
• Microbiology

Background:

• Tuberculosis (TB) remains a significant global health challenge, exacerbated by the rise of drug-resistant strains.
• Lanostane triterpenoids from Ganoderma species exhibit promising biological activities, including potential antitubercular effects.
• The need for novel therapeutic agents against Mycobacterium tuberculosis is critical.

Purpose of the Study:

• To semynthetically modify naturally occurring lanostane triterpenoids isolated from Ganoderma australe.
• To evaluate the antitubercular activity of the modified compounds against various strains of Mycobacterium tuberculosis.
• To identify novel drug candidates with improved potency and broader spectrum activity.

Main Methods:

• Isolation of lanostane triterpenoids from mycelial cultures of Ganoderma australe.
• Semisynthetic structural modifications of the isolated natural products.
• In vitro evaluation of antitubercular activity against Mycobacterium tuberculosis H37Ra, H37Rv, and drug-resistant strains.

Main Results:

• A novel synthetic compound, GA003 (9), was synthesized from a natural lanostane triterpenoid.
• GA003 exhibited significantly enhanced antitubercular activity compared to the parent natural compound against Mycobacterium tuberculosis H37Ra.
• GA003 demonstrated potent activity against the virulent H37Rv strain and extensively drug-resistant tuberculosis strains.

Conclusions:

• Semisynthetic modification of natural lanostane triterpenoids can yield compounds with superior antitubercular potency.
• GA003 represents a promising lead compound for the development of new drugs against tuberculosis, including multidrug-resistant and extensively drug-resistant forms.
• Further investigation into GA003 and related analogs is warranted for potential clinical application in TB treatment.